Topical treatment of seasonal allergic rhinitis with a beta-adrenoceptor stimulant (KWD 2131).

Abstract

During 4 weeks of the grass pollen season in the south of Sweden 27 patients with seasonal allergic rhinitis were treated topically with a beta-adrenoceptor stimulant, KWD 2131, which in an earlier rhinomanometric study had shown a prophylactic effect at nasal allergen provocations in hay-fever patients. A clinical effect of KWD 2131 could not be documented in this randomized placebo-controlled, double-blind comparative study. The results contribute to conclusions in the clinical implications of rhinomanometric data.

• Authors: G Svensson
• Journal: Rhinology (Rhinology) Vol. 20 Issue 3 Pg. 159-66 (Sep 1982) ISSN: 0300-0729 [Print] Netherlands
• PMID: 6127780 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Adrenergic beta-Agonists
• KWD 2131
• Terbutaline

Topics

• Administration, Intranasal
• Adolescent
• Adrenergic beta-Agonists
• Adult
• Clinical Trials as Topic
• Double-Blind Method
• Female
• Humans
• Male
• Middle Aged
• Rhinitis, Allergic, Seasonal (diagnosis, drug therapy)
• Terbutaline (administration & dosage, analogs & derivatives)